Tellgen

Tellgen Equity Ratio

The Equity Ratio of Tellgen (300642.SZ) as of Oct 26, 2026 is 69.35 %. In the previous year, Equity Ratio was 86.19 % — a change of -19.54% (lower).

Equity Ratio

69.35 %

YoY

-19.54%

Last updated:

Equity Ratio of Tellgen is 2025 69.35 % . Equity Ratio of Tellgen was 2024 86.19 % . It decreases by -19.54% lower compared to the previous year.

The Tellgen Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
92.87 CNY
Jan 1, 2019
93.75 CNY
Jan 1, 2020
92.33 CNY
Jan 1, 2021
92.99 CNY
Jan 1, 2022
88.45 CNY
Jan 1, 2023
91.00 CNY
Jan 1, 2024
86.19 CNY
Jan 1, 2025
69.35 CNY
The Tellgen Equity Ratio history
YEAREquity RatioYoY
69.35 %-19.54%
86.19 %-5.28%
91.00 %+2.88%
88.45 %-4.89%
92.99 %+0.72%
92.33 %-1.52%
93.75 %+0.96%
92.87 %-3.06%
95.80 %+13.01%
84.77 %+1.72%
83.33 %+2.87%
81.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Equity Ratio of Tellgen is 69.35 % in 2025.

Equity Ratio of Tellgen changed from 86.19 % to 69.35 %, representing a -19.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Tellgen since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Tellgen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Tellgen

All Key Metrics — Tellgen